J Med Chem. 2010 Feb 25;53(4):1546-62.

Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.

Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M.

Source

Laboratoire d'Innovation Thérapeutique, UMR 7200 CNRS/Université de Strasbourg, Faculte de Pharmacie, 74 route du Rhin, BP60024, 67401 Illkirch, France.

Abstract

Very few nonpeptide oxytocin agonists have currently been reported, and none of them seem suitable for the in vivo investigation of the oxytocin mediated functions. In an attempt to rationalize the design of better tools, we have systematically studied the structural determinants of the affinity and efficacy of representative ligands of the V(1a), V(2), and OT receptor subtypes. Despite apparently obvious similarity between the ligand structures on one hand, and between the receptor subtypes on the other hand, the binding affinity and the functional activity profiles of truncated and hybrid ligands highlight the subtlety of ligand-receptor interactions for obtaining nonpeptide OT receptor agonists.

PMID:: 20104850; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Chemical Information

BindingDB

Supplemental Content

Save items

Related citations in PubMed

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. [J Med Chem. 2002]
Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T. J Med Chem. 2002 Jun 6; 45(12):2579-88.
Review Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. [Prog Brain Res. 2008]
Review Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Prog Brain Res. 2008; 170:473-512.
A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors. [Eur J Pharmacol. 2002]
A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors.
Lemaire W, O'Brien JA, Burno M, Chaudhary AG, Dean DC, Williams PD, Freidinger RM, Pettibone DJ, Williams DL Jr. Eur J Pharmacol. 2002 Aug 16; 450(1):19-28.
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. [Br J Pharmacol. 2001]
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A. Br J Pharmacol. 2001 Jul; 133(5):746-54.
Review Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. [Biochem Soc Trans. 2007]
Review Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges.
Chini B, Manning M. Biochem Soc Trans. 2007 Aug; 35(Pt 4):737-41.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
BioAssay
PubChem BioAssay experiments on the biological activities of small molecules that cite the current articles. The depositors of BioAssay data provide these references.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Subtlety of the structure-affinity and structure-efficacy relationships around a...
Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.
J Med Chem. 2010 Feb 25 ;53(4):1546-62.

PubMed
Disorders of inadequate iron.
Disorders of inadequate iron.
Hosp Pract (Off Ed). 1991 Apr ;26 Suppl 3:25-9.

PubMed
Stilbene glucoside from Polygonum multiflorum Thunb.: a novel natural inhibitor ...
Stilbene glucoside from Polygonum multiflorum Thunb.: a novel natural inhibitor of advanced glycation end product formation by trapping of methylglyoxal.
J Agric Food Chem. 2010 Feb 24 ;58(4):2239-45.

PubMed
An index of fatal toxicity for drugs of misuse.
An index of fatal toxicity for drugs of misuse.
Hum Psychopharmacol. 2010 Mar ;25(2):162-6.

PubMed
Addition of carvedilol to University Wisconsin solution improves rat steatotic a...
Addition of carvedilol to University Wisconsin solution improves rat steatotic and nonsteatotic liver preservation.
Liver Transpl. 2010 Feb ;16(2):163-71.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Chemical Information

Supplemental Content

Save items

Related citations in PubMed

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information